Effect of Aficamten Compared with Metoprolol on Echocardiographic Measures in Symptomatic Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM

Effect of Aficamten Compared with Metoprolol on Cardiac Structure and Function in Symptomatic Obstructive Hypertrophic Cardiomyopathy: A Prespecified Analysis of MAPLE-HCM

Low Incidence of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis From the REDWOOD-HCM, SEQUOIA-HCM and FOREST-HCM Trials

Incidence and Impact of Atrial Fibrillation in Patients with Obstructive HCM Treated with Aficamten: An Analysis From the REDWOOD-HCM, SEQUOIA-HCM, and FOREST-HCM Trials

Aficamten in Patients with Obstructive Hypertrophic Cardiomyopathy: An Integrated Safety Analysis

Aficamten vs Metoprolol as Monotherapy for Symptomatic Obstructive Hypertrophic Cardiomyopathy

Aficamten or Metoprolol Monotherapy for Obstructive Hypertrophic Cardiomyopathy

Aficamten Treatment for Symptomatic Obstructive Hypertrophic Cardiomyopathy: 48-Week Results From FOREST-HCM

Evaluation of Cytochrome P450 2C9, 2C19, and 2D6 Inhibition on the Pharmacokinetics of Aficamten in Healthy Participants

Aficamten vs Metoprolol for Obstructive Hypertrophic Cardiomyopathy: MAPLE-HCM Rationale, Study Design, and Baseline Characteristics